LQCL2603 - CMLE - Laboratory Evaluation of Isolated ALP Elevation: A Case Study Highlighting the Role of Bone Turnover Markers-LQCL2603

LQCL2603 - Educational Activity

Pdf Summary

This document presents a clinical chemistry case study focused on evaluating an isolated elevation in total alkaline phosphatase (t-ALP) and using bone turnover markers to diagnose and monitor Paget disease of bone (PDB). A 65-year-old man collapses during exercise, reports months of left hip pain, and has a markedly elevated t-ALP (780 U/L) on a comprehensive metabolic panel, while other liver-associated tests (AST, ALT, bilirubin, GGT) and renal markers are normal. The laboratory professional confirms the result is valid and explains that the normal liver enzymes make a hepatic source unlikely, raising suspicion for a bone-derived ALP elevation.<br /><br />Pelvic radiographs show classic Paget-like changes (cortical thickening and focal bone loss), prompting ordering of bone-specific alkaline phosphatase (b-ALP) to confirm a skeletal source. The narrative reviews PDB as a common metabolic bone disorder in older adults, often incidentally detected via elevated t-ALP or imaging. Pathophysiology involves dysregulated, excessive osteoclast resorption followed by compensatory but disorganized osteoblast-driven bone formation, producing enlarged, highly vascular, structurally weak bone prone to deformity and fracture. Symptoms, when present, include pain, osteoarthritis, nerve compression, and fractures.<br /><br />The document highlights bone turnover markers (BTMs) for diagnosis and monitoring: b-ALP (formation), P1NP (collagen synthesis/formation; particularly sensitive in active PDB), CTX (resorption), and osteocalcin (formation/turnover). It emphasizes variability among assays and patient factors, recommending baseline and serial testing under consistent conditions.<br /><br />In the case, b-ALP is elevated (34.3 µg/L), with mildly elevated P1NP and elevated CTX, supporting active disease. The patient undergoes bone scan imaging for extent and starts bisphosphonate therapy, which inhibits osteoclasts and lowers BTMs over time; response is monitored with serial markers and periodic imaging to reduce complications.

Keywords

isolated elevated alkaline phosphatase

total alkaline phosphatase (t-ALP)

bone-specific alkaline phosphatase (b-ALP)

Paget disease of bone (PDB)

bone turnover markers (BTMs)

P1NP

CTX

osteoclast-mediated bone resorption

bisphosphonate therapy

bone scan imaging